Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 20 of 5804
-
Simple balloon trick after stroke could help patients walk again
Disease control Not yet recruitingThe main goal of this study is to find out if a new, quick "brain rescue" procedure can help people recover better from a severe stroke caused by a large vessel occlusion. When someone has this type of stroke, doctors often perform a procedure called an endovascular thrombectomy…
Phase: NA • Sponsor: Shanghai Jiao Tong University Affiliated Sixth People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Daily pill aims to tackle weight and diabetes together
Disease control Not yet recruitingThis is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM. Participants will be randomized to aleniglipron or placebo for a total of 7…
Phase: PHASE3 • Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug aims to outperform current therapy in Hard-to-Treat breast cancer
Disease control Not yet recruitingThis trial is a randomized, open-label, multicenter Phase II study designed to evaluate the efficacy and safety of BL-M07D1 in patients with unresectable locally recurrent or metastatic HR-positive, HER2-low expressing breast cancer.
Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Engineered immune cells take on lupus kidney disease
Disease control Not yet recruitingThe primary objective of this trial is to evaluate the efficacy and safety of FT819, comprised of allogeneic T cells that express a CD19-targeted CAR, following bendamustine administration in participants with refractory moderate-to-severe lupus nephritis, as assessed by the prop…
Phase: PHASE2 • Sponsor: Fate Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New antibody combo aims to outperform standard therapy in Tough-to-Treat colorectal cancer
Disease control Recruiting nowThe purpose of this trial is to evaluate how well petosemtamab in combination with chemotherapy works against colorectal cancer located on the left side of the colon that cannot be safely removed by surgery or has spread to other parts of the body. Participants will receive eith…
Phase: PHASE3 • Sponsor: Genmab • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New drug aims to outsmart Chemotherapy-Resistant ovarian cancer
Disease control Not yet recruitingThis is a randomized, open-label, multicenter Phase III clinical study designed to evaluate the efficacy and safety of SYS6043 versus investigator's choice chemotherapy in participants with platinum-resistant ovarian cancer, primary peritoneal, or fallopian tube cancer.
Phase: PHASE3 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Engineered immune cells take aim at childhood autoimmune diseases
Disease control Not yet recruitingThis is a single-arm, open-label, phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD06-05, a universal CD19/BCMA dual-targeting chimeric antigen receptor T-cell (CAR-T), in pediatric and adolescent patients with ref…
Phase: EARLY_PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Psychedelic therapy aims to break the relapse cycle in alcoholism and depression
Disease control Recruiting nowUp to 40% of individuals with alcohol use disorder (AUD) experience depression, which increases the risk of early relapse. Depression can cause relapse to occur 3 times faster in individuals with AUD who experience depressive symptoms at discharge. No treatments have been approve…
Phase: PHASE3 • Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New Immune-Targeting drug could boost stomach cancer treatment
Disease control Recruiting nowClaudin 18.2 or CLDN18.2 is a protein found on cells in the digestive system. It is also found in some tumors. Researchers are looking at ways to attack CLDN18.2 to help control tumors. ASP2138 is thought to bind to CLDN18.2 and a type of immune cell called a T cell. This "tells"…
Phase: PHASE3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Short-Course radiation may boost immunotherapy and chemo for stomach cancer
Disease control Not yet recruitingThis study is a prospective, open-label, multicenter, randomized controlled clinical trial designed to enroll patients with previously untreated, resectable locally advanced adenocarcinoma of the upper stomach or gastroesophageal junction. After providing informed consent and mee…
Phase: NA • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Personalized vaccine takes aim at recurrent brain tumors
Disease control Not yet recruitingThis is a single-center, open-label, dose-escalation, multiple-dose investigator-initiated trial (IIT). The trial aims to evaluate the safety and tolerability of autologous dendritic cell injection sensitized with tumor neoantigens (YS247) in participants with recurrent or progre…
Phase: NA • Sponsor: Huanhu Hospital Affiliated to Tianjin Medical University • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
BiTE antibodies could unlock transplants for 'Incompatible' kidney patients
Disease control Not yet recruitingThis study is a prospective, open-label, two-arm exploratory clinical trial aimed at evaluating the safety and efficacy of Bispecific T-cell Engager (BiTE) therapies in refractory, highly sensitized kidney transplant candidates. Patients with end-stage renal disease (ESRD) who ha…
Phase: PHASE4 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New combo aims to boost breast cancer remission before surgery
Disease control Not yet recruitingTNBC is a heterogeneous disease with distinct pathological, genetic, and clinical features among subtypes. Treatment results for high-risk primary TNBC remain poor compared to other breast cancer subtypes. Preoperative chemotherapy is the standard of care for patients with stage …
Phase: PHASE3 • Sponsor: West German Study Group • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
AI takes on lymphoma: personalized drug cocktail aims to outsmart cancer in older patients
Disease control Not yet recruitingThis is a prospective, open-label, multicenter, randomized controlled study in older treatment-naive patients with LBCL. Participants will be stratified into different risk groups using an AI-based multimodal model. Those classified as intermediate- or high-risk will be randomize…
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Experimental CAR-T therapy takes on tough lupus cases
Disease control Not yet recruitingThe purpose of this study is to evaluate the safety and tolerability of P-CD19CD20-ALLO1 in participants with highly active, severe, refractory SLE with or without lupus nephritis (LN). This study includes a dose-escalation stage followed by an expansion stage. It will also evalu…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New triple therapy could extend lives in stomach cancer
Disease control Not yet recruitingGastric/GEJ adenocarcinomas are aggressive tumors with a high probability of death. Current treatment guidelines include two-drug cytotoxic chemotherapy with a fluoropyrimidine (mFOLFOX6: capecitabine or fluorouracil) and a platinum-based agent (CapOx: oxaliplatin or cisplatin). …
Phase: PHASE3 • Sponsor: Suzhou Transcenta Therapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Immunotherapy cocktail aims to shrink head and neck tumors before surgery
Disease control Not yet recruitingThis study compares two short pre-surgery treatments for locally advanced head and neck squamous cell cancer to see which one keeps the cancer from coming back longer. Eligible patients (18-70 years, newly diagnosed, operable) will be randomly assigned to receive either toripali…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Experimental brain cancer therapy targets tumors directly
Disease control Not yet recruitingThis is a Phase II trial to evaluate the safety, tolerability, efficacy, and PK/ pharmacodynamic profiles of MT027 injected via ICV in participants with recurrent or progressive IDH-wildtype glioblastoma (WHO 2021 CNS Grade 4), who have previously received standard of care (SOC) …
Phase: PHASE2 • Sponsor: T-MAXIMUM Pharmaceutical Inc • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Could MDMA help veterans heal from PTSD? new study investigates
Symptom relief Recruiting nowA Phase 2, single-center, fixed-dose, open-label study will explore the efficacy, safety, and tolerability of a 120 mg dose of oral MDMA followed by a supplemental dose of 60 mg MDMA in conjunction with therapy in individual versus group settings for adult veterans diagnosed with…
Phase: PHASE2 • Sponsor: Sunstone Medical • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
New hope for kids with lymphoma: drug combo may replace harsh chemo
Disease control Not yet recruitingA prospective, multicenter, randomized controlled clinical study of camrelizumab in combination with ivarmacitinib as first-line treatment for pediatric classical Hodgkin lymphoma
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC